Low-grade glioma (LGG, WHO grade 2 — IDH-mutant) · None

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Track	standard
Linked regimen	`None`

ID	`IND-RHABDOID-PREDISPOSITION-CARRIER-SURVEILLANCE`
Type	Indication
Status	reviewed 2026-05-19 \| pending_clinical_signoff
Diseases	`DIS-GLIOMA-LOW-GRADE`
Sources	`SRC-NCCN-CNS-2025` `SRC-NCCN-GENETIC-FAMILIAL-BREAST-OVARIAN-2025`

Notes

STUB pending two-Co-Lead signoff per CHARTER §6.1 dev-mode. Standard-track RTPS1/RTPS2 confirmed-carrier surveillance per Foulkes et al. 2017 / EU-RHAB consensus. Disease anchor DIS-GLIOMA-LOW-GRADE used as closest CNS entity available; actual surveilled spectrum is ATRT / extracranial MRT / SCCOHT (SMARCA4) — distinction surfaced in rationale + do_not_do.

Used By

Indication

IND-RHABDOID-PREDISPOSITION-CARRIER-INTENSIFIED - IND-RHABDOID-PREDISPOSITION-CARRIER-INTENSIFIED